If the U.S. wants a better deal on some medicines, the federal government could try pegging prices to what is paid by Japan, the U.K., and the Canadian province of Ontario.

Why? A new study finds that prices paid for 79 different brand-name prescription drugs averaged 3.2 to 4.1 times higher in the U.S. and that if Medicare Part D had used the same pricing as in those other locations, the federal health care program could have saved nearly $73 billion last year. The analysis also found that the longer a drug was on the market, the larger the difference in pricing grew.

Unlock this article by subscribing to STAT Plus and enjoy your first 30 days free!

GET STARTED

What is it?

STAT Plus is a premium subscription that delivers daily market-moving biopharma coverage and in-depth science reporting from a team with decades of industry experience.

What's included?

  • Authoritative biopharma coverage and analysis, interviews with industry pioneers, policy analysis, and first looks at cutting edge laboratories and early stage research
  • Subscriber-only networking events and panel discussions across the country
  • Monthly subscriber-only live chats with our reporters and experts in the field
  • Discounted tickets to industry events and early-bird access to industry reports

Leave a Comment

Please enter your name.
Please enter a comment.

Sign up for our Daily Recap newsletter

A roundup of STAT’s top stories of the day in science and medicine

Privacy Policy